Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study

被引:16
|
作者
Zettl, Uwe K. [1 ]
Bauer-Steinhusen, Ulrike [2 ]
Glaser, Thomas [2 ]
Hechenbichler, Klaus [3 ]
Limmroth, Volker [4 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Rostock, Germany
[2] Bayer Vital GmbH, Immunol & Ophthalmol, Med Neurol, Leverkusen, Germany
[3] Inst Dr Schauerte, Oberhaching, Germany
[4] Stadt Klinikum Koln Merheim, Klin Neurol, Cologne, Germany
来源
BMC NEUROLOGY | 2013年 / 13卷
关键词
Adherence; Interferon beta-1b; Non-interventional study; Electronic diary; Multiple sclerosis; Immunomodulation; DEPRESSIVE SYMPTOMS; CES-D; THERAPY; POPULATION; VALIDATION; MEDICATION; IMPACT; COSTS; DRUGS; CARE;
D O I
10.1186/1471-2377-13-117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis is a chronic, incurable, demyelinating disease that requires long-term treatment. Rates of non-adherence to prescribed therapy of up to 50% have been reported for chronic diseases. Strategies to improve treatment adherence are therefore of the utmost importance. This study will evaluate the effect of using electronic and paper diaries on treatment adherence to interferon beta-1b in patients with a first clinical isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). Here we report on the study design and results of baseline assessments. Methods: Patients were recruited into a prospective national multicenter cohort study for an observational period of 2 years. At the start of the study, patients opted to use a digital (DiD) or paper diary (PD) to document self-administered injections of interferon beta-1b. Adherence to treatment will be assessed on the dropout rate at the end of the observation period and on the regularity of injections every other day at 6-month intervals. Patient-related health outcomes will also be evaluated. Results: 700 patients with a mean age of 38.3 (SD 10.3) years and a mean duration of disease since diagnosis of 3.6 (SD 5.9) years were enrolled. 383 patients opted for the digital diary, 192 of which included an injection reminder. Significantly more male than female patients opted for the DiD. Only gender was identified as a factor influencing the decision for DiD or PD. Based on rating scales, a significantly higher proportion of women had depressive comorbidities at baseline. Conclusions: Demographic characteristics of the two cohorts were similar at baseline. More women chose a paper diary, and more had depression at baseline. These imbalances will be addressed in the analysis of the study as possible confounders influencing long-term treatment adherence in the digital and paper diary cohorts.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy
    Zettl, Uwe Klaus
    Bauer-Steinhusen, Ulrike
    Glaser, Thomas
    Hechenbichler, Klaus
    Hecker, Michael
    BMC NEUROLOGY, 2016, 16
  • [12] Arthritis during interferon beta-1b treatment in multiple sclerosis
    Altintas, A
    Alici, Y
    Melikoglu, M
    Siva, A
    MULTIPLE SCLEROSIS, 2002, 8 (06): : 534 - 536
  • [13] New aspects in the treatment of multiple sclerosis with interferon beta-1b
    Kappos, L
    JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 4) : 1 - 1
  • [14] Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
    Marziniak, Martin
    Meuth, Sven
    ADVANCES IN THERAPY, 2014, 31 (09) : 915 - 931
  • [15] Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
    Penner, Iris-Katharina
    Stemper, Brigitte
    Calabrese, Pasquale
    Freedman, Mark S.
    Polman, Chris H.
    Edan, Gilles
    Hartung, Hans-Peter
    Miller, David H.
    Montalban, Xavier
    Barkhof, Frederik
    Pleimes, Dirk
    Lanius, Vivian
    Pohl, Christoph
    Kappos, Ludwig
    Sandbrink, Rupert
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (10) : 1466 - 1471
  • [16] Current status of interferon beta-1b in the treatment of multiple sclerosis
    Hartung, HP
    MEDIZINISCHE KLINIK, 2001, 96 : 11 - 16
  • [18] New aspects in the treatment of multiple sclerosis with interferon beta-1b
    Ludwig Kappos
    Journal of Neurology, 2004, 251 : iv1 - iv1
  • [19] Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
    Martin Marziniak
    Sven Meuth
    Advances in Therapy, 2014, 31 : 915 - 931
  • [20] Multiple Sclerosis, interferon beta-1b and depression - A prospective investigation
    Feinstein, A
    O'Connor, P
    Feinstein, K
    JOURNAL OF NEUROLOGY, 2002, 249 (07) : 815 - 820